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The neglected zoonotic diseases (NZDs) have been all but eradicated in wealthier 
countries but remain major causes of ill-health and mortality in over 80 countries across 
Africa, Asia, and Latin America. The nature of neglect for the NZDs has been ascribed, 
in part, to underreporting resulting in an underestimation of their global burden that, 
together with a lack of advocacy, downgrades their relevance to policy-makers and 
funding agencies. While this may be the case for many NZDs, for rabies this is not 
the case. The global burden estimates for rabies (931,600 DALYs) more than justify 
prioritizing rabies control building on the strong advocacy platforms, functioning at 
local, regional, and global levels (including the Global Alliance for Rabies Control), and 
commitments from WHO, OIE, and FAO. Simple effective tools for rabies control exist 
together with blueprints for operationalizing control, yet, despite elimination targets 
being set, no global affirmative action has been taken. Rabies control demands activities 
both in the short term and over a long period of time to achieve the desired cumulative 
gains. Despite the availability of effective vaccines and messaging tools, rabies will not 
be sustainably controlled in the near future without long-term financial commitment, 
particularly as disease incidence decreases and other health priorities take hold. 
While rabies control is usually perceived as a public good, public private partnerships 
could prove equally effective in addressing endemic rabies through harnessing social 
investment and demonstrating the cost-effectiveness of control. It is acknowledged that 
greater attention to navigating local realities in planning and implementation is essential 
to ensuring that rabies, and other neglected diseases, are controlled sustainably. In the 
shadows of resource and institutional limitations in the veterinary sector in low- and 
middle-income countries, sufficient funding is required so that top-down interventions for 
rabies can more explicitly engage with local project organization capacity and affected 
communities in the long term. Development Impact Bonds have the potential to secure 
the financing required to deliver effective rabies control.
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inTRODUCTiOn
More than a decade of advocacy has resulted in ambitious control and elimination targets for 
neglected tropical diseases (NTDs) set by WHO for 2020. Partnerships have been formed to raise 
funds and provide advocacy for NTD control, including the Global Programme to Eliminate 
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Lymphatic Filariasis1 and the Global Network for NTDs.2 
Advocacy resulted in the 2012 London Declaration3 and WHO 
Roadmap to accelerate the work to overcome the global impact 
of 17 NTDs,4 followed by the World Health Assembly (WHA) 
Resolution WHA66.12 on NTDS in May 2013. However, for the 
neglected zoonotic diseases (NZDs) that were included in this 
Roadmap (rabies, echinococcosis hydatid disease, leishmaniasis, 
Trypanosoma brucei rhodesiense sleeping sickness, and Taenia 
solium cysticercosis), little progress has been made. Anthrax, 
brucellosis, and bovine TB were not included in the resolution.
Rabies is one of the most feared human diseases, estimated 
to cause some 55,000 deaths each year, predominately among 
children and the rural poor in Asia and Africa (1–3). The rabies 
virus has a simple route of transmission; via saliva from the bite 
of an infected animal, the rabies virus invades the central nervous 
system and, in the absence of postexposure prophylaxis (PEP), 
is fatal once clinical signs appear (4). Symptoms in dogs can be 
non-specific but often include “hydrophobia,” hypersalivation, 
respiratory difficulties, biting, and aggression. Since the vast 
majority of human rabies cases are caused by domestic dogs (5) 
and an effective vaccine is available, dog vaccination is the most 
effective control strategy together with dog population manage-
ment, movement regulations, and the promotion of responsible 
dog ownership (5–7). A number of initiatives have been under-
taken (8–12), and a combination of intensive canine vaccination 
and surveillance efforts, implemented since the 1980s in Latin 
America, has shown dramatic progress (13).
Eliminating infection from dogs reduces the demand for 
costly PEP, although the relationship is not always as predicted 
and may vary considerably (14, 15). Despite all the evidence of the 
benefits of targeting the domestic canine reservoir, dog vaccina-
tion remains under-prioritized in most low- and middle-income 
countries (LMIC) with competing health issues and limited 
resources. Despite a number of successful initiatives having been 
implemented, erroneous perceptions of operational constraints 
among policy-makers (lack of knowledge about the dog popula-
tion, inadequate resources, and wildlife transmission) are barriers 
to vaccination (5).
To successfully eliminate rabies, vaccination must reach at 
least 70% of a dog population over consecutive years, yet, despite 
the feasibility of elimination, programs in Africa struggle with 
reaching high levels of coverage (16); vaccination rates lower 
than 30% are considered a “waste of resources” (5). Despite good 
quality vaccines for dogs, a genuine science of rabies elimination 
is needed (17) to understand complex social–ecological deter-
minants of vaccination effectiveness (18). Vaccination coverage 
declines rapidly in dog populations with high turnover rates (19). 
Most dogs in Africa are owned by a family but are free roaming 
and generally young; often half of dogs are less than 1 year of age 
(20–23). Dog bite data, used to infer numbers of human deaths, 
were used to calculate the threshold density for rabies persistence 
as 4.5 dogs/km2 (1).
1 http://www.filariasis.org/.
2 http://globalnetwork.org/.
3 http://unitingtocombatntds.org/resource/london-declaration.
4 http://www.who.int/neglected_diseases/NTD_RoadMap_2012_Fullversion.pdf.
Validated estimates of dog populations are essential for 
planning successful mass dog vaccinations yet in most cases 
are lacking (12); for example, a study in Tanzania showed that 
the dog population was six times larger than the official esti-
mate (23). Interventions are influenced by local dog ownership 
practices; attitudes toward dogs; the ability and willingness of 
owners to handle their dogs; the location of vaccination points, 
and the extent of information dissemination and knowledge 
of rabies, all of which influence compliance (8, 22, 24, 25). 
Despite higher costs, house-to-house strategies were neces-
sary to achieve 70% coverage in pastoralist communities in 
Northern Tanzania (26). Capacity and working norms of 
implementing organizations are also key; most campaigns are 
planned nationally and delivered at district and subdistrict 
level. In many African LMIC, a legacy of structural adjustment 
in the veterinary sector had resulted in reduced capacity in the 
animal health sector. Large remote geographical areas together 
with low salaries, insufficient resources, and rigid bureaucratic 
norms can further inhibit such campaigns, which depend, to 
a large degree, on adapting strategies to fit community needs. 
However, even with cheap and effective dog vaccines available 
and with burdens and costs well understood, there is no guar-
antee that elimination will be easily achieved (27).
From a human health perspective, a dog bite wound requires 
cleaning and a postexposure treatment (PET) vaccination is 
essential, but expensive. As dog-to-dog transmission drives rabies 
epidemics, PET alone will not eliminate rabies. From an animal 
health perspective, rabies in cattle, and not dogs, is considered 
more important, because of the greater economic value of a cow 
relative to a dog, so national rabies vaccination programs are not 
prioritized.
THe PROBLeM wiTH RABieS COnTROL
Neglected zoonotic diseases may be described as the neglected 
NTDs, beset by problems of underreporting that tends to under-
estimate their global burden and so diminishes their relevance 
to policy-makers and funding agencies. Interventions in the 
animal reservoir for NZDs (mass vaccination, drug treatment, 
and education) must be supported and operationalized across 
health and agriculture ministries. Long-term national and 
regional plans for elimination demand significant buy-in from 
both human and animal health sectors. When a full cross-sector 
analysis is undertaken and all stake-holder benefits (monetary/
non-monetary) are taken into account, interventions for NZDs 
can become highly cost-effective, and among all neglected 
NZDs, dog rabies elimination is the lowest hanging fruit, with 
all the necessary tools for elimination already available (28, 29). 
However, for rabies, the cost benefits of vaccinating dogs may take 
many years to be realized and requires universal high coverage 
to be achieved annually. For example, mathematical models of 
rabies control in Ndjamena, Chad, suggest the cumulative cost 
of dog rabies mass vaccination and human PET was equal to the 
cumulative cost of PET alone after 6 years and only became more 
cost-effective after 7 years (15). Costs of rabies control are borne 
almost entirely by people in the developing world where >99% 
of all fatalities occur and dog owners have not been willing to 
FiGURe 1 | The annual cash-flow requirements, the performance-related payments to investors, and impact on rabies transmission dynamics for a 
hypothetical Development impact Bond (DiB). The total cost of the DIB is US$ 6.45 million, including Year 1 establishment costs, with US$ 5.45 million 
financed by investors (Years 1–6) and US$ 1 million by the Government (Years 7–10 in the post-elimination maintenance phase). This excludes the ongoing 
government spend providing the routine rabies surveillance platform independent of any specific strengthening or refinements needed to deliver the DIB. The 
model assumes mass vaccination of 70% of dogs in year 1 (US$ 1.8 million) and then a second round of 70% vaccination spread over 3 years (total cost $2.5 
million). Costs for community messaging are included throughout the program. Based on achieving the vaccination targets, the investors receive a payment at the 
end of Year 4 equal to 66% of the DIB spend over the first 5 years. The remaining payments to the investors in Years 6–8 are linked to reduced rabies transmission 
and are back-loaded to incentivize a successful transition to embedding the maintenance phase under government spend. The surveillance system is embedded 
into national veterinary and public health services and assumes an annual cost of US$ 250,000, which includes provision for reactive ring vaccination following 
confirmed sporadic canine rabies cases and continued use of postexposure prophylaxis following confirmed exposure. The total return to investors is US$ 7.2 
million, representing an internal rate of return of 8%.
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pay the full costs of vaccination, indicating that rabies control 
should be considered a public good (30).
There are proven systems to identify those individuals exposed 
to the rabies virus, most often following a rabid dog bite, and 
ensure PET is administered promptly to avoid death from rabies, 
which is otherwise inevitable once the victim starts to display 
clinical symptoms. Any death due to dog-mediated rabies is 
a failure of the public and veterinary health systems, but the 
main constraint to widespread implementation is finance. Poor 
countries do not have access to the funds required to develop and 
deliver an appropriate control strategy tailored to their epidemio-
logical conditions that can be implemented over sufficient time to 
unlock and sustain public health and economic benefits.
DeveLOPMenT iMPACT BOnDS 
(DiBs)—A new APPROACH TO FUnDinG 
RABieS COnTROL
The tools for effective control and the evidence that they work 
have been around for a long time; the constraining factor has been 
the financing to implement sustained efforts at scale. Traditional 
financing streams for NTD control in resource poor settings, 
particularly grant funding through international governmental 
donors, charitable organizations, or private institutions, have not 
been available at the levels required to combat the continued 
burden of rabies. The failure to secure the necessary financing 
is in part due to the inability to compete against other pressing 
infectious disease burdens, which have historically secured the 
majority of the resources going into NTD control. What can be 
done to break this deadlock and mobilize additional resources 
and unlock the benefits of achievable rabies control?
A new model of sustainable investment in rabies control is 
required, and DIBs is one approach that potentially could secure 
the financing required to deliver effective rabies control. We 
argue that financing structure of a DIB is particularly well suited 
to financing rabies control and so provides a highly compelling 
case to donors interested in controlling NTDs in a highly cost-
effective manner (Figure 1).
Development Impact Bonds are a form of Social Impact Bonds 
(SIBs), which are themselves a form of payment for results (31). 
SIBs have been applied to address a variety of societal problems 
primarily across the developed world, and although the number 
and size of transaction is small, the market is growing rapidly 
FiGURe 2 | Plausible Development impact Bond (DiB) structure for rabies control. The flow of money from the National Government to embed rabies 
surveillance post-vaccination control into the veterinary and public health systems may be through the SPV established to deliver the DIB or may be independent of 
the DIB structure but counts toward the overall delivery costs. Note, the structure was developed based on the work conducted with Global Alliance for Rabies 
Control (GARC) and is applicable for rabies control in general with other advocacy agencies playing similar roles to GARC.
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(31). In developing settings, DIBs, while far from being a panacea, 
have been advocated as potentially important in helping address 
a broad range of inequalities including improved public health 
provision (32), childhood development (33), and infectious 
disease control (34).
More broadly, DIBs are one example of a new form of social 
impact financing in which donor or government payments are 
structured around the delivery of specific outcomes. There is 
significant and growing interest among traditional develop-
ment donors (such as DFID, USAID, and The World Bank), 
philanthropic institutions (such as UBS Optimus Foundation, 
Children’s Investment Fund Foundation, Bill & Melinda Gates 
Foundation, and Rockefeller Foundation), and the emerging class 
of impact investors, in the use of DIBs to effectively deliver impact 
in developing countries.5 One of the most advanced propositions 
currently in development is the area-wide control of zoonotic 
sleeping sickness in Uganda (34).
5 https://www.gov.uk/government/news/uk-development-bonds-will-combat- 
global-poverty.
Development Impact Bonds use private investment to provide 
up-front risk capital for development programs, only calling on 
donor (or government) funding to repay capital, plus a potential 
return (i.e., premium), once clearly defined and measured devel-
opment outcomes are achieved. DIBs have the potential to attract 
new capital from impact investors motivated by both social and 
financial returns. By transferring the risk of program failure to 
these investors, DIBs bring a greater focus on implementation 
and delivery of successful results. In this way, DIBs also satisfy 
the growing demands that public funding, be it internal or spent 
on overseas aid, should be paid on successful results and in a 
transparent manner (Figure 2).
There are characteristics of infectious disease control programs 
in general, and rabies control in particular, which map neatly onto 
a DIB including
(1) Strong evidence base that successful program delivery is 
 technically achievable.
 Development Impact Bonds are about  scaling proven 
interventions and primarily look to  shift implementation 
risk (not technical risk) from outcome payers to investors. 
The evidence base for effective rabies control has been 
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validated and is strong. The constraints to implementation 
are known to be financial and operational. A consensus has 
emerged in the international community about the basis for 
implementing control with detail guidelines, The Blueprint 
for Rabies Prevention and Control (2014) developed by the 
Partners for Rabies Prevention (10), which includes the 
Stepwise Approach to Rabies Elimination tool (developed 
by FAO, the Global Alliance for Rabies Control, and other 
partners) and the approach endorsed by the WHO–OIE–
FAO tripartite.6
 Models for designing and running effective rabies vac-
cination campaigns have been developed and trialed in 
a variety of developing country settings. For example, 
Tanzania, where rabies is endemic with an estimated 
1,500 deaths each year (35), was among three countries 
selected by the WHO for large-scale rabies elimination 
demonstration trials between 2009 and 2013—funded by 
the Bill and Melinda Gates Foundation (BMGF) (see http://
www.who.int/rabies/bmgf_who_project/en/index.html).
(2) Substantial up-front investment is needed to unlock long-term 
net benefits.
 The ideal cash-flow profile of the DIB (front loaded invest-
ment followed by long-term lower cash needs) mirrors the 
high up-front effort needed to interrupt rabies transmission 
followed by reduced effort to maintaining disease control. In 
poor countries, the money is rarely available to cover these 
up-front costs while traditional donor funding does not 
advance large amounts of cash; in the DIB, private investors 
provide the capital needed up front, at risk.
(3) Affordable and sustainable maintenance of long-term impact.
 Successful dog rabies mass vaccinations (providing sufficient 
coverage over sufficient time) will interrupt transmission 
allowing a shift to a disease-free maintenance phase based on 
surveillance, reactive vaccination, and appropriate human 
case management. Maintenance costs are significantly lower 
than the up-front costs of mass vaccination [e.g., Ref. (15, 
36)], and there is the potential to embed the maintenance 
activities in routine public and veterinary health systems 
funded by the country government to ensure long-term 
sustainability beyond the end of the DIB.
(4) Successful implementation requires coordination between 
multiple partners.
 Controlling rabies requires engagement from partners across 
ministries and the private and public sector and demands 
a “One Health” approach in which there is close coordina-
tion between the veterinary and public health sectors. The 
investment structure in the DIB ensure a common drive to 
deliver specific outcomes providing a unified focus for the 
veterinary and human health delivery partners.
(5) Tractable and affordable measure of outcomes that are valid 
indicators of long-term impact.
 Tractable and affordable measure of outcomes will trigger 
payments from the outcome funders to the investors. For 
6 http://www.rabiesblueprint.com/.
rabies, there exist established, validated, and robust diagnos-
tic procedures to confirm positive rabies samples as well as 
case recording systems to monitor human rabies exposure. 
These measures provide a basis for quantifying the reduc-
tion in disease transmission relative to a pre-intervention 
baseline. The growing economic literature investigating the 
burden of rabies provides the evidence basis for understand-
ing the impact unlocked by long-term reduction in rabies 
transmission.
STRUCTURinG A DiB FOR RABieS 
inTeRvenTiOn
The structure of a DIB applied to rabies would partition interven-
tions into four phases:
(1) Pre-implementation phase in which the detailed delivery 
plan is developed; baseline incidence data collected; existing 
public and veterinary health surveillance systems are, where 
necessary, strengthened and refined to provide the basis 
for tracking success across all phases of the intervention; 
reporting systems developed and tested; DIB infrastructure 
(e.g., establishment of special purpose vehicle for DIB con-
tracting) and recruitment/contracting of delivery partners 
secured; payment triggers agreed; and an independent 
outcome auditor appointed.
(2) Suppression phase in which the mass vaccination campaigns 
are implemented at national level; routine reporting imple-
mented; and audit of vaccination coverage by the independ-
ent outcome measurement group is conducted.
(3) Consolidation phase in which there is a shift from mass 
vaccination to surveillance and reactive vaccination follow-
ing confirmed canine cases; protection of borders; audit of 
canine rabies incidence and suspect rabid dog bites.
(4) Post-elimination maintenance phase in which the surveil-
lance capacity is embedded in government services and fully 
financed by the government.
For rabies, ideally DIB payment triggers would be split between 
a partial return of capital based on delivery of mass vaccination 
coverage (measured against the 70% target threshold) and a series 
of outcome payments (back-loaded to incentivize long-term 
sustainability) linked to a reduction in disease incidence in the 
reservoir dog population and also exposure in humans.
COnCLUSiOn
The major constraint to progressing beyond a concept and 
launching a rabies-DIB is the lack of active engagement from a 
payer. Discussions with leading overseas development agencies, 
who have to act as the primary payers if DIBs are ever to be a 
significant source of financing in LMICs, have confirmed an 
interest among donors about DIBs in principle but in practice 
revealed a lack of internal expertise and capacity in engaging in 
the detailed planning of a DIB. This is not unexpected given the 
novelty of DIBs as a financing alternative to direct grant support. 
6Welburn et al. Innovative Financing of Rabies Control
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Moreover, novel structures are perceived as risky and so avoided. 
Part of the risk is the perception issues that a successful DIB will 
cost the payer more than direct grant funding. Another aspect 
of the risk is the lack of any large-scale working examples of a 
DIB, which itself is a function of the lack of donor backing to 
test a DIB and develop the evidence. To break this catch 22 situ-
ation the evidence generated from SIBs from developed settings 
should start to emerge to help support, or not, the theory of the 
impact bond financing approach. Despite increased advocacy for 
rabies, it should be noted that rabies is not perceived as a priority 
disease, even among the NTDs, and donors are positioning other 
development issues in the pipeline for possible DIB financing 
ahead of rabies.
Several approaches may help progress the DIB concept for 
NTD in general, and rabies more specifically, to accelerate the 
involvement of traditional government aid agencies:
First, an emerging theme in DIB design is the central impor-
tance of identifying an appropriate outcome measure and that 
can be tractably, affordably, and verifiably measured to provide a 
robust quantitative basis for triggering payments. This is central 
to all DIBs. These issues are complex for the NTDs, which are 
characterized by a high degree of underreporting in affected 
human populations and a particular problem for NZDs, where 
the work on sleeping sickness (37) and rabies (1) points to using 
measures of transmission in the animal reservoir population as 
a proxy measure for human disease burden. Potential locations 
suitable for pilot DIB-financed interventions are characterized by 
having an active, well-respected academic research group with a 
track-record of peer-reviewed papers detailing a robust under-
standing of the disease epidemiology and empirical evidence 
of successful pilot interventions; engaged local veterinary and 
human public health agencies and relevant central government 
support.
Second, although a single international donor may be reluc-
tant to finance a DIB in full, there may be potential to attract 
a co-payer, such as a foundation or a national government. 
This would catalyze the involvement of donor agencies and 
stimulate the broader DIB market. In the case of rabies, the 
blueprint for rabies control can be used as a starting point to 
divide the task of global rabies elimination into a series of DIBs 
investments, scaled to investors. A philanthropic foundation 
that has previous been funding rabies control (e.g., The BMGF) 
could consider switching spend to cover part of a DIB payment. 
Similarly, a country that has previously benefited from donor 
funding for rabies control (e.g., South Africa where The BMGF 
has funded rabies vaccination through WHO) could undertake 
to cover part of the outcome payments and attract additional 
donors to secure the balance of outcome payment. A general 
DIB structure and site-specific example for rabies elimination 
in Chad have been developed and are currently market tested 
with investors and donors (36). The framework exists to develop 
other site-specific DIB proposal for rabies control, which local 
governments and non-governmental advocacy agencies can 
market to potential payers.
Finally, consideration should be given to how rabies control 
could be integrated into other NTD/NZD intervention platforms. 
While any one NTD/NZD may not be prioritized by a donor, 
an integrated approach that delivers multiple impacts through a 
common delivery platform could be attractive and highly cost 
effective. With a burden of 931,600 DALYs (38), the burden for 
rabies is higher that Chagas, cutaneous Leishmaniasis, trypano-
somiasis, cysticercosis, echinococcisis, trachoma, yellow fever, 
Ebola, trichuriasis and leprosy (39), and programs could be 
aligned so adding value. For example, strengthening veterinary 
public health surveillance systems to track rabies cases could 
be beneficial for tracking the impact of interventions against 
several diseases, while awareness messaging could be extended 
to deliver important health messages against multiple disease in 
which dogs are important reservoirs of disease (including cuta-
neous Leishmaniasis and echinococcisis) (40–44). If additional 
interventions can be delivered at marginal costs utilizing the 
same delivery teams and infrastructure, then cost-effectiveness 
of each intervention is improved and the likelihood of donor 
support potentially increased. The integration of rabies into other 
large-scale intervention programs was an emerging theme at the 
recent Partners for Rabies Prevention meeting (May 2015). This 
could form the basis of a more compelling DIB, which develop-
ing country governments could prioritize and potentially unlock 
donor support.
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